NOTIFICATION

The following notification is being circulated in accordance with Article 10.6

|  |  |
| --- | --- |
| **1.** | **Notifying Member:** United States of America  **If applicable, name of local government involved (Article 3.2 and 7.2):** |
| **2.** | **Agency responsible:** Food and Drug Administration (FDA), Health and Human Services (HHS) [1816]  **Name and address (including telephone and fax numbers, email and website addresses, if available) of agency or authority designated to handle comments regarding the notification shall be indicated if different from above:**  Please submit comments to: USA WTO TBT Enquiry Point, Email: [usatbtep@nist.gov](mailto:usatbtep@nist.gov) |
| **3.** | **Notified under Article 2.9.2 [****],** **2.10.1 [****],** **5.6.2 [****],** **5.7.1 [****],** **other** **[X]:** |
| **4.** | **Products covered (HS or CCCN where applicable, otherwise national tariff heading. ICS numbers may be provided in addition, where applicable):** Silver nitrate; Domestic safety (ICS 13.120), Production in the chemical industry (ICS 71.020), Inorganic chemicals (ICS 71.060) |
| **5.** | **Title, number of pages and language(s) of the notified document:** Listing of Color Additives Exempt From Certification; Silver Nitrate (5 page(s), in English) |
| **6.** | **Description of content:** Final rule - The Food and Drug Administration (FDA or we) is amending the color additive regulations to provide for the safe use of silver nitrate as a color additive in professional-use only cosmetics to color eyebrows and eyelashes. This action is in response to a color additive petition (CAP) filed by GW Cosmetics GmbH. |
| **7.** | **Objective and rationale, including the nature of urgent problems where applicable:** Prevention of deceptive practices and consumer protection; Protection of human health or safety |
| **8.** | **Relevant documents:**  86 Federal Register (FR) 55494, 6 October 2021; Title 21 Code of Federal Regulations (CFR) Part 21 and 73: <https://www.govinfo.gov/content/pkg/FR-2021-10-06/html/2021-21755.htm> <https://www.govinfo.gov/content/pkg/FR-2021-10-06/pdf/2021-21755.pdf>  This final rule is identified by Docket Number FDA-2018-C-0617. The Docket Folder is available on Regulations.gov at <https://www.regulations.gov/docket/FDA-2018-C-0617/document> and provides access to primary and supporting documents as well as comments received. Documents are also accessible from [Regulations.gov](http://www.regulations.gov/) by searching the Docket Number.  This rule is effective 8 November 2021. See section VIII for further information on the filing of objections. Submit either electronic or written objections and requests for a hearing on the final rule by 5 November 2021. WTO Members and their stakeholders are asked to submit comments to the [USA TBT Enquiry Point](mailto:usatbtep@nist.gov). Comments received by the USA TBT Enquiry Point from WTO Members and their stakeholders will be shared with the regulator and will also be submitted to the [Docket](https://www.regulations.gov/docket/FDA-2018-C-0617/document) on Regulations.gov if received within the comment period. |
| **9.** | **Proposed date of adoption:** 6 October 2021  **Proposed date of entry into force:** 8 November 2021 |
| **10.** | **Final date for comments:** 5 November 2021 |
| **11.** | **Texts available from: National enquiry point [** **]** **or address, telephone and fax numbers and email and website addresses, if available, of other body:**  <https://members.wto.org/crnattachments/2021/TBT/USA/21_6494_00_e.pdf> |